Mobile Application Based Lactulose Titration for Prevention of Hepatic Encephalopathy
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- Mayo Clinic
- 入组人数
- 50
- 试验地点
- 1
- 主要终点
- Achievement of daily stool goal
研究概览
简要总结
This study is being done to assess the safety and efficacy of using mobile application-based Bristol stool scale to titrate lactulose in prevention episodes of hepatic encephalopathy.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Prevention
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —(Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Ability to provide written, informed consent.
- •Currently taking lactulose daily for prevention of hepatic encephalopathy.
排除标准
- •Recent change in dosing of opioid medication.
- •Previous Colorectal Surgery.
- •Active diarrheal illness.
- •Lack of smartphone or other smart device at home.
研究组 & 干预措施
Mobile application-based Bristol stool scale
Subjects with cirrhosis who are taking lactulose for the treatment of hepatic encephalopathy will download the Dieta mobile application on their mobile device and take a photo of each bowel movement using the Dieta application
干预措施: Dieta mobile application (Other)
结局指标
主要结局
Achievement of daily stool goal
时间窗: 4 weeks
Number of subject to achieve daily stool goal, determined if use of the mobile application leads to improved rates of meeting daily stool goal (3-4 stools per day of Bristol Stool Scale 3-4)
次要结局
未报告次要终点
研究者
Douglas (Doug) A. Simonetto
Principal Investigator
Mayo Clinic
